209 research outputs found

    Pollution atmosphérique et climat

    Get PDF
    National audienceClimate change and air quality are closely related: through the policy measures implemented to mitigate these major environmental threats but also through the geophysical processes that drive them. We designed, developed and implemented a comprehensive regional air quality and climate modelling system to investigate future air quality in Europe taking into account the combined pressure of future climate change and long range transport. Using the prospective scenarios of the last generation of pathways for both climate change (emissions of well mixed greenhouse gases) and air pollutants, we can provide a quantitative view into the possible future air quality in Europe. We find that ozone pollution will decrease substantially under the most stringent scenario but the efforts of the air quality legislation will be adversely compensated by the penalty of global warming and long range transport for the business as usual scenario. For particulate matter, the projected reduction of emissions efficiently reduces exposure levels.Changement climatique et qualité de l'air sont intimement liés : à travers les politiques de gestion mises en oeuvre pour atténuer ces menaces environnementales majeures mais aussi à travers les processus géophysiques qui les gouvernent. Afin de pouvoir étudier l'évolution de la pollution atmosphérique en Europe en prenant en compte l'influence conjointe du changement climatique et du transport à longue distance, nous avons conçu, développé et mis en oeuvre un système complet de modélisation régionale du climat et de la qualité de l'air. En utilisant des scénarios prospectifs de dernière génération relatifs au changement climatique (émissions de gaz à effet de serre) mais aussi pour les polluants à courte durée de vie, nous avons pu proposer une quantification de l'évolution future de la qualité de l'air en Europe. D'après le scénario le plus volontariste, la pollution liée à l'ozone sera réduite de manière substantielle mais les efforts positifs induits par les politiques de gestion de la qualité de l'air seront contrebalancés par le changement climatique et le transport à longue distance pour le scénario statu-quo. En ce qui concerne les particules, les réductions d'émissions futures réduiront de manière efficace les niveaux d'exposition

    Phenotype and outcomes of very early onset and early onset inflammatory bowel diseases in a Montreal pediatric cohort

    Get PDF
    ObjectivesThe incidence of very-early-onset inflammatory bowel disease (VEO-IBD) and early-onset IBD (EO-IBD) is increasing. Here, we report their phenotype and outcomes in a Montreal pediatric cohort.MethodsWe analyzed data from patients diagnosed with IBD between January 2014 and December 2018 from the CHU Sainte-Justine. The primary endpoint was to compare the phenotypes of VEO-IBD and EO-IBD. The secondary endpoints involved comparing outcomes and rates of steroid-free clinical remission (SFCR) at 12 (±2) months (m) post-diagnosis and at last follow-up.Results28 (14 males) and 67 (34 males) patients were diagnosed with VEO-IBD and EO-IBD, respectively. Crohn's disease (CD) was more prevalent in EO-IBD (64.2% vs. 39.3%), whereas unclassified colitis (IBD-U) was diagnosed in 28.6% of VEO-IBD vs. 10.4% of EO-IBD (p < 0.03). Ulcerative colitis (UC) and IBD-U predominantly presented as pancolitis in both groups (VEO-IBD: 76.5% vs. EO-IBD: 70.8%). Combining all disease subtypes, histological upper GI lesions were found in 57.2% of VEO-IBD vs. 83.6% of EO-IBD (p < 0.009). In each subtype, no differential histological signature (activity, eosinophils, apoptotic bodies, granulomas) was observed between both groups. At 12 m post-diagnosis, 60.8% of VEO-IBD and 62.7% of EO-IBD patients were in SFCR. At a median follow-up of 56 m, SFCR was observed in 85.7% of VEO-IBD vs. 85.0% of EO-IBD patients.ConclusionThe rate of patients in SFCR at 1-year post-diagnosis and at the end of follow-up did not significantly differ between both groups

    Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers

    Get PDF
    Familial hypocholesterolemia, namely abetalipoproteinemia, hypobetalipoproteinemia and chylomicron retention disease (CRD), are rare genetic diseases that cause malnutrition, failure to thrive, growth failure and vitamin E deficiency, as well as other complications. Recently, the gene implicated in CRD was identified. The diagnosis is often delayed because symptoms are nonspecific. Treatment and follow-up remain poorly defined

    Experimental Tuberculosis in the Wistar Rat: A Model for Protective Immunity and Control of Infection

    Get PDF
    BACKGROUND: Despite the availability of many animal models for tuberculosis (TB) research, there still exists a need for better understanding of the quiescent stage of disease observed in many humans. Here, we explored the use of the Wistar rat model for the study of protective immunity and control of Mycobacterium tuberculosis (Mtb) infection. METHODOLOGY/PRINCIPAL FINDINGS: The kinetics of bacillary growth, evaluated by the colony stimulating assay (CFU) and the extent of lung pathology in Mtb infected Wistar rats were dependent on the virulence of the strains and the size of the infecting inoculums. Bacillary growth control was associated with induction of T helper type 1 (Th1) activation, the magnitude of which was also Mtb strain and dose dependent. Histopathology analysis of the infected lungs demonstrated the formation of well organized granulomas comprising epithelioid cells, multinucleated giant cells and foamy macrophages surrounded by large numbers of lymphocytes. The late stage subclinical form of disease was reactivated by immunosuppression leading to increased lung CFU. CONCLUSION: The Wistar rat is a valuable model for better understanding host-pathogen interactions that result in control of Mtb infection and potentially establishment of latent TB. These properties together with the ease of manipulation, relatively low cost and well established use of rats in toxicology and pharmacokinetic analyses make the rat a good animal model for TB drug discovery
    corecore